NasdaqGS - Delayed Quote • USD
Karyopharm Therapeutics Inc. (KPTI)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 5:06 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -0.33 | -0.31 | -1.23 | -1.01 |
| Low Estimate | -0.37 | -0.34 | -1.33 | -1.27 |
| High Estimate | -0.28 | -0.27 | -1.09 | -0.77 |
| Year Ago EPS | -0.3 | -0.29 | -1.25 | -1.23 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 34.47M | 36.42M | 146.52M | 164.74M |
| Low Estimate | 31.7M | 34.6M | 142.44M | 130.2M |
| High Estimate | 38.36M | 39.4M | 150.84M | 209.72M |
| Year Ago Sales | 36.6M | 37.58M | 146.03M | 146.52M |
| Sales Growth (year/est) | -5.80% | -3.10% | 0.30% | 12.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.37 | -0.34 | -0.28 | -0.31 |
| EPS Actual | -0.3 | -0.29 | -0.3 | -0.36 |
| Difference | 0.07 | 0.05 | -0.02 | -0.05 |
| Surprise % | 18.90% | 14.70% | -7.10% | -16.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.33 | -0.31 | -1.23 | -1.01 |
| 7 Days Ago | -0.33 | -0.31 | -1.23 | -1.01 |
| 30 Days Ago | -0.33 | -0.31 | -1.23 | -1.01 |
| 60 Days Ago | -0.3 | -0.3 | -1.1 | -1.01 |
| 90 Days Ago | -0.3 | -0.29 | -1.09 | -0.96 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | KPTI | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -10.00% | -- | -- | 1.60% |
| Next Qtr. | -6.90% | -- | -- | 10.50% |
| Current Year | 1.60% | -- | -- | 5.20% |
| Next Year | 17.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -30.30% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 11/3/2023 |
| Maintains | RBC Capital: Outperform to Outperform | 11/3/2023 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 8/7/2023 |
| Maintains | Piper Sandler: Overweight to Overweight | 8/3/2023 |
| Maintains | RBC Capital: Outperform to Outperform | 8/3/2023 |
Related Tickers
CHRS Coherus BioSciences, Inc.
2.0700
+3.50%
PROK ProKidney Corp.
2.0400
-15.00%
TGTX TG Therapeutics, Inc.
13.78
-1.50%
RLYB Rallybio Corporation
1.7600
+5.39%
HRTX Heron Therapeutics, Inc.
2.6400
-2.58%
ADAP Adaptimmune Therapeutics plc
0.9767
+8.72%
TSVT 2seventy bio, Inc.
4.5200
-2.59%
SAGE Sage Therapeutics, Inc.
13.33
+2.26%
MRNS Marinus Pharmaceuticals, Inc.
1.3800
-2.13%
OCUL Ocular Therapeutix, Inc.
5.22
-10.92%